Moshe Rozenbaum

Recent coverage of Nano Dimension has focused on significant corporate restructuring, including board changes following an agreement with activist investor Murchinson and a leadership transition to an interim CEO, alongside questions about the company's strategic pivot toward AI healthcare. The company has reported Q3FY26 revenue growth of 18.7% year-over-year and undertaken operational moves such as relocating its Essemtec U.S. headquarters, though coverage has also reflected uncertainty surrounding the company's direction and its previously announced healthcare-focused initiatives.

Summarized from the headlines below; see each source for the full story.